MDS Patients with Autoimmune Disorders Responsive To Vidaza

26 Dec. 2012

Findings presented at the 2012 annual meeting of the American Society of Hematology (ASCO) in Chicago earlier this month suggest Myelodysplastic syndromes patients with autoimmune disorders may be more responsive to treatment with Vidaza or Dacogen than patients without autoimmune disorders.

Click here to read the full article on The MDS Beacon.